Minnesota Chemoprevention Consortium (MC^2) Award
A joint initiative of the Masonic Cancer Center and the University of Minnesota Hormel Institute
The objective of the Minnesota Chemoprevention Consortium (MC2) Seed Grant is to stimulate collaborative research on topics directly relevant to the effective development and delivery of cancer chemoprevention agents, either naturally occurring or synthetic. Proposals must involve a regional collaboration between at least two University of Minnesota Masonic Cancer Center members, one located at The Hormel Institute in Austin and the other located at the Masonic Cancer Center Twin Cities campus.
Grantees
Prevention of prostate tumorigenesis by combinations of indole-3-carbinol and silibinin
Fekadu Kassie, DVM, PhD, Department of Veterinary Clinical Sciences, College of Veterinary Medicine
Yibin Deng, MD, PhD, Hormel Institute
Skin-homing Bone Marrow Derived Cells: Novel Targets for Chemoprevention
Rebecca Morris, PhD, Laboratory of Stem Cells and Cancer, The Hormel Institute
Alexander Meves, MD, Department of Dermatology, Mayo Clinic
A Highly Potent Chemopreventive Agent for Lung Tumorigenesis and Mechanisms
Chengguo Xing, PhD, Department of Medicinal Chemistry, College of Pharmacy
Pramod Upadhyaya, PhD, Department of Laboratory Medicine and Pathology, Medical School
Assessment of Glucobrassicin/I3C Uptake via a Whole Food Matrix using Urinary DIM
Naomi Fujioka, MD, Department of Medicine, Medical School
Stephen Hecht, PhD, Department of Laboratory Medicine and Pathology, Medical School